Overview

Price chart · mood · technical indicators

NRIX

Nurix Therapeutics Incstock Healthcare

Biotechnology

$15.4823.84%Current Market Mood:Neutral

Market Mood

Price Range (1Y)

$8.20$22.50

Current: $15.48

Idea: EMA

1Y Return

+44.4%

Sharpe 3Y

0.82

Market Comparison

vs Healthcare Sector & Biotechnology Industry

NRIX

+23.84%

1Y Performance

Fundamentals

Updated daily after market close

P/E ratio—

EPS (TTM)$-3.170.0% YoY

Profit margin0.0%HEALTHCARE

Market cap$1.69BSmall cap

Wall Street coverage

$30.18median target· current $16.86 (+79.0%)17 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: —
PEG ratio: —
P/B: 3.74
P/S (TTM): 23.58
EV/EBITDA: -3.35

Profitability & growth

ROE (TTM): -61.4%
Operating margin: -1479.0%
Revenue growth YoY: -66.1%
Dividend yield: —
Beta: 1.88

Last earnings

Apr 8, 2026 · Estimate $-0.83 · Reported $-0.79

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Nurix Therapeutics Inc

Company profile

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company is headquartered in San Francisco, California.

Classification

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 1600 SIERRA POINT PARKWAY, BRISBANE, CA
Fiscal year end: November
Latest quarter: Feb 28, 2026

Market cap$1.69B

Shares outstanding$103.4M

52W high$22.50

52W low$8.20

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer

Overview

NRIX

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Nurix Therapeutics (NRIX) CLO sells 8,148 shares, exercises 3,422 options

Nurix Therapeutics chief legal officer sells $135,252 in stock

Christine Ring executes 10b5-1 sales of NRIX shares (NRIX)

Nurix Therapeutics Price Target Maintained With a $30.00/Share by BTIG

A Look At Nurix Therapeutics (NRIX) Valuation After New NX-5948 Data And EHA Congress Selection

Nurix Therapeutics : NRIX

Nurix Therapeutics (NRIX) director granted 31,250 stock options at $15.86

Nurix Therapeutics (NRIX) director awarded 31,250 stock options at $15.86 strike

Nurix Therapeutics (NRIX) director receives 31,250-share stock option grant

Nurix Therapeutics (NRIX) shareholders approve directors, PwC audit and say-on-pay

Nurix Therapeutics (NRIX) director awarded 31,250 stock options

Nurix Therapeutics (NRIX) director receives grant of 31,250 stock options at $15.86

Nurix Therapeutics (NRIX) director gets 31,250 stock options at $15.86

Nurix Therapeutics Shareholders Back Directors and Governance Proposals

Nurix Therapeutics (NRIX) director awarded 31,250 stock options

Deep Track files 6.17% ownership in Nurix Therapeutics (NRIX) — 6.35M shares

Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting

Did Nurix’s (NRIX) EHA Oral BTK Degrader Data Just Reframe Its Oncology Investment Narrative?

Experimental hives pill from Nurix shows 25x lab potency vs remibrutinib

Nurix Therapeutics stock (US67079U1007): Analysts see 144% upside potential

About Nurix Therapeutics Inc

Classification

Company profile

NRIX

Market Comparison

NRIX Market Analysis

Overview

NRIX

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Nurix Therapeutics (NRIX) CLO sells 8,148 shares, exercises 3,422 options

Nurix Therapeutics chief legal officer sells $135,252 in stock

Christine Ring executes 10b5-1 sales of NRIX shares (NRIX)

Nurix Therapeutics Price Target Maintained With a $30.00/Share by BTIG

A Look At Nurix Therapeutics (NRIX) Valuation After New NX-5948 Data And EHA Congress Selection

Nurix Therapeutics : NRIX

Nurix Therapeutics (NRIX) director granted 31,250 stock options at $15.86

Nurix Therapeutics (NRIX) director awarded 31,250 stock options at $15.86 strike

Nurix Therapeutics (NRIX) director receives 31,250-share stock option grant

Nurix Therapeutics (NRIX) shareholders approve directors, PwC audit and say-on-pay

Nurix Therapeutics (NRIX) director awarded 31,250 stock options

Nurix Therapeutics (NRIX) director receives grant of 31,250 stock options at $15.86

Nurix Therapeutics (NRIX) director gets 31,250 stock options at $15.86

Nurix Therapeutics Shareholders Back Directors and Governance Proposals

Nurix Therapeutics (NRIX) director awarded 31,250 stock options

Deep Track files 6.17% ownership in Nurix Therapeutics (NRIX) — 6.35M shares

Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting

Did Nurix’s (NRIX) EHA Oral BTK Degrader Data Just Reframe Its Oncology Investment Narrative?

Experimental hives pill from Nurix shows 25x lab potency vs remibrutinib

Nurix Therapeutics stock (US67079U1007): Analysts see 144% upside potential

About Nurix Therapeutics Inc

Classification

Company profile

NRIX

Market Comparison